Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin
Sponsor: Astellas Pharma Korea, Inc.
Listed as NCT03076112, this PHASE3 trial focuses on Type 2 Diabetes Mellitus and remains completed. Sponsored by Astellas Pharma Korea, Inc., it has been updated 11 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Apr 2021 — Nov 2022 [monthly]
Recruiting PHASE3
▶ Show 6 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE3
-
Nov 2019 — Jan 2021 [monthly]
Recruiting PHASE3
-
Oct 2018 — Nov 2019 [monthly]
Recruiting PHASE3
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE3
-
May 2017 — Jun 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Apr 2017 — May 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Korea, Inc.
- Seoul National University Bundang Hospital
For direct contact, visit the study record on ClinicalTrials.gov .